More information about AKEBIA THERAPEUTICS INC.

Global leadership in hypoxia inducible factor (HIF) biology. Dedicated to advancing care for serious disease. Pursuing advances across multiple disease states. We were founded in 2007 to discover and develop novel therapeutic solutions leveraging hypoxia inducible factor—or HIF—biology, a primary regulator involved in multiple major biological pathways. Our strategy is to develop novel therapeutics for patients based on the biology of HIF and to commercialize products for patients with kidney disease, beginning with vadadustat (also known as AKB-6548) for patients with anemia secondary to chronic kidney disease (CKD).